去铁酮对重型地中海贫血患者免疫状态和细胞因子模式的影响。
Effects of deferiprone on immune status and cytokine pattern in thalassaemia major.
作者信息
Del Vecchio Giovanni Carlo, Schettini Federico, Piacente Laura, De Santis Attilio, Giordano Paola, De Mattia Domenico
机构信息
Dipartimento di Biomedicina dell'Età Evolutiva, Università di Bari, Italia.
出版信息
Acta Haematol. 2002;108(3):144-9. doi: 10.1159/000064705.
OBJECTIVE
The present study was undertaken to evaluate the possible occurrence of immunological abnormalities in thalassaemia major patients treated with deferiprone (L1).
METHODS
Longitudinal observational cohort study.
RESULTS
The absolute number of CD8+ lymphocytes was high and the CD4/CD8 ratio low before L1 treatment; these parameters returned to normal after 3 months of L1 treatment. TNF-alpha, IL-2 and IL-2sRalpha were elevated before L1 treatment (11.83 +/- 1.75, 11.75 +/- 3.91, 1,409 +/- 621 pg/ml, respectively), while IL-6 was normal (2.58 +/- 0.79 pg/ml). After 12 months of treatment, IL-10 was higher than in previous periods, although always within the normal range. TNF-alpha, IL-2 and IL-2sRalpha returned to normal after 12, 6, and 3 months of L1 treatment, respectively.
目的
本研究旨在评估接受去铁酮（L1）治疗的重型地中海贫血患者可能出现的免疫异常情况。
方法
纵向观察队列研究。
结果
在L1治疗前，CD8 + 淋巴细胞绝对数较高，CD4/CD8比值较低；L1治疗3个月后这些参数恢复正常。L1治疗前TNF-α、IL-2和IL-2sRα升高（分别为11.83±1.75、11.75±3.91、1409±621 pg/ml），而IL-6正常（2.58±0.79 pg/ml）。治疗12个月后，IL-10虽始终在正常范围内，但高于之前各时期。TNF-α、IL-2和IL-2sRα分别在L1治疗12、6和3个月后恢复正常。
Zotero 插件